{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:01:47Z","timestamp":1793289707781,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0236"],"award-info":[{"award-number":["2022YFS0236"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Science and Technology of Sichuan Province","award":["2021YFS0027"],"award-info":[{"award-number":["2021YFS0027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-024-02190-w","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T04:10:03Z","timestamp":1733458203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion"],"prefix":"10.1186","volume":"23","author":[{"given":"Guo-qian","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2190_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.4254\/wjh.v16.i5.766","volume":"16","author":"M Vij","year":"2024","unstructured":"Vij M, Veerankutty FH, Rammohan A, et al. Combined hepatocellular cholangiocarcinoma: a clinicopathological update. World J Hepatol. 2024;16:766-75.","journal-title":"World J Hepatol"},{"issue":"5","key":"2190_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00432-024-05781-8","volume":"150","author":"S Gurzu","year":"2024","unstructured":"Gurzu S, Szodorai R, Jung I, Banias L. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies. J Cancer Res Clin Oncol. 2024;150(5):270.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2190_CR3","doi-asserted-by":"publisher","first-page":"100745","DOI":"10.1016\/j.jhepr.2023.100745","volume":"5","author":"MPAW Claasen","year":"2023","unstructured":"Claasen MPAW, Ivanics T, Beumer BR, et al. An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma. JHEP Rep. 2023;5(6):100745.","journal-title":"JHEP Rep"},{"issue":"10","key":"2190_CR4","doi-asserted-by":"publisher","first-page":"e1774","DOI":"10.1002\/onco.13893","volume":"26","author":"PD Chen","year":"2021","unstructured":"Chen PD, Chen LJ, Chang YJ, Chang YJ. Long-term survival of combined Hepatocellular-Cholangiocarcinoma: a Nationwide Study. Oncologist. 2021;26(10):e1774-85.","journal-title":"Oncologist"},{"key":"2190_CR5","doi-asserted-by":"crossref","unstructured":"Auer TA, Collettini F, Segger L et al. Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and perspectives for Combined Hepatocellular-Cholangiocarcinoma. Cancers (Basel). 2023; 1520230508.","DOI":"10.3390\/cancers15092655"},{"key":"2190_CR6","doi-asserted-by":"publisher","first-page":"20230713","DOI":"10.3390\/cancers15143609","volume":"15","author":"L Schwenk","year":"2023","unstructured":"Schwenk L, Rohland O, Ali-Deeb A, et al. Liver transplantation for Incidental Cholangiocarcinoma or combined hepatocellular Carcinoma\/Cholangiocarcinoma-Own experiences and Review of the literature. Cancers (Basel). 2023;15:20230713.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2190_CR7","first-page":"210","volume":"12","author":"KJ Chu","year":"2024","unstructured":"Chu KJ, Kawaguchi Y, Wang H, Jiang XQ, Hasegawa K. Update on the diagnosis and treatment of combined Hepatocellular Cholangiocarcinoma. J Clin Transl Hepatol. 2024;12(2):210-7.","journal-title":"J Clin Transl Hepatol"},{"key":"2190_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00428-024-03792-x","volume":"484","author":"M Sasaki","year":"2024","unstructured":"Sasaki M, Sato Y, Nakanuma Y. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Virchows Arch. 2024;484:915-23.","journal-title":"Virchows Arch"},{"issue":"5","key":"2190_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jhep.2021.01.035","volume":"74","author":"A Beaufr\u00e8re","year":"2021","unstructured":"Beaufr\u00e8re A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol. 2021;74(5):1212-24.","journal-title":"J Hepatol"},{"issue":"1","key":"2190_CR10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1186\/s12885-024-12970-8","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, He D, Lu ZJ, et al. Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma. BMC Cancer. 2024;24(1):1232.","journal-title":"BMC Cancer"},{"key":"2190_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11523-023-01024-x","volume":"19","author":"JE Frampton","year":"2024","unstructured":"Frampton JE, Pemigatinib. A review in Advanced Cholangiocarcinoma. Target Oncol. 2024;19:107-14.","journal-title":"Target Oncol"},{"key":"2190_CR12","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.2147\/CMAR.S330710","volume":"13","author":"M Salati","year":"2021","unstructured":"Salati M, Caputo F, Baldessari C, et al. The evolving role of FGFR2 inhibitors in Intrahepatic Cholangiocarcinoma: from Molecular Biology to Clinical Targeting. Cancer Manag Res. 2021;13:7747-57.","journal-title":"Cancer Manag Res"},{"key":"2190_CR13","doi-asserted-by":"crossref","unstructured":"Murugesan K, Sharaf R, Montesion M et al. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol. 2021;5:PO.20.00397.","DOI":"10.1200\/PO.20.00397"},{"key":"2190_CR14","doi-asserted-by":"publisher","first-page":"e2200390","DOI":"10.1200\/PO.22.00390","volume":"6","author":"L De La Vega","year":"2022","unstructured":"De La Vega L, Comeau L, Sallan H. Rare FGFR oncogenic alterations in sequenced Pediatric Solid and Brain tumors Suggest FGFR is a relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022;6:e2200390.","journal-title":"JCO Precis Oncol"},{"key":"2190_CR15","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","volume":"12","author":"Wu","year":"2022","unstructured":"Wu Q, Zhen Y, Shi L, et al. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov 2022; 12: 1378-1395.","journal-title":"Cancer Discov"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-02190-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T05:02:51Z","timestamp":1733461371000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-02190-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-02190-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of West China Second Hospital of Sichuan University and followed the Declaration of Helsinki principles (Approval No. 2021-114). Written informed consent was obtained from the minor(s)\u2019 legal guardian\/next of kin for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication was obtained from all the participants involved in our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}